Skip to Main Content

Late last year, several high-profile partnerships between big pharma companies and health tech startups fell apart — raising questions about whether culture clash and financial pressures would doom such alliances.

But in the months since, pharma’s interest in businesses trying to rethink how people get their medications has proved resilient. The latest sign of that came on Friday: Johnson & Johnson’s innovation arm will make an investment in Thirty Madison, the company offering telemedicine visits and online prescriptions for drugs for hair loss, migraines, and acid reflux.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!